Shares of Ultragenyx Pharmaceutical Inc. soared in Tuesday’s extended session after the company announced positive results from a phase 3 study of a drug to treat x-linked hypophosphatemia, a genetic kidney disorder. “Patients treated with burosumab demonstrated a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels compared to 8% on placebo,” said the company in a statement. As the next step, the drug company plans to hold discussions with regulatory agencies in the U.S. and Europe. The study was jointly conducted with Japan’s Kyowa Hakko Kirin Co. Ultragenyx jumped 19% after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News